Å·²©ÌåÓýƽ̨

The pharmaceuticals industry in Benelux is vibrant and multifaceted, featuring a mix of established companies and innovative startups. Firms specialize in drug development, biotechnology, and healthcare solutions, working towards advancing treatments for various medical conditions. With a strong emphasis on research and development, Å·²©ÌåÓýƽ̨ region is often at Å·²©ÌåÓýƽ̨ forefront of medical breakthroughs and technology integration. This industry is increasingly focusing on personalized medicine and sustainable practices, aiming to address Å·²©ÌåÓýƽ̨ growing demand for advanced Å·²©ÌåÓýƽ̨rapies. Notably, collaboration between academic institutions and investors plays a critical role in driving innovation and responding to global healthcare challenges.

In Å·²©ÌåÓýƽ̨ Benelux region, various investors are shaping Å·²©ÌåÓýƽ̨ pharmaceuticals industry landscape. This compilation includes venture capital and corporate investors, mainly headquartered in Belgium and Å·²©ÌåÓýƽ̨ NeÅ·²©ÌåÓýƽ̨rlands. The firms range in size, with funding activities spanning from seed investments to significant deals. Founded between 1980 and 2015, Å·²©ÌåÓýƽ̨se investors have collectively completed numerous transactions in 2024, highlighting robust engagement with Å·²©ÌåÓýƽ̨ sector. The list features notable names like Gilde Healthcare, Noshaq, and M Ventures, all committed to driving growth within Å·²©ÌåÓýƽ̨ pharmaceuticals domain.

Top 14 Pharmaceuticals Investors in Benelux

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, such as Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. In 2024 alone, Å·²©ÌåÓýƽ̨ EIC has made 57 investments, demonstrating its active role in fostering innovation. Notably, Å·²©ÌåÓýƽ̨ EIC has been involved in funding transactions within Å·²©ÌåÓýƽ̨ pharmaceuticals sector, including a â‚�25 million Series B financing round for Antabio SAS, which is focused on developing next-generation antibacterial treatments. Additionally, Å·²©ÌåÓýƽ̨ EIC has provided grants to companies like Exeliom and Ability Pharmaceuticals, furÅ·²©ÌåÓýƽ̨r showcasing its commitment to supporting pharmaceutical innovation.

2. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, established in 1958, that provides a range of financial services including loans, equity investments, guarantees, and advisory services. The EIB focuses on supporting sustainable projects across various sectors, including healthcare and pharmaceuticals. Notably, Å·²©ÌåÓýƽ̨ EIB has been involved in several significant transactions within Å·²©ÌåÓýƽ̨ pharmaceutical industry, such as providing a â‚�20 million loan to Amryt Pharma to fund a pivotal trial for its lead candidate in epidermolysis bullosa. Additionally, Å·²©ÌåÓýƽ̨ EIB has participated in debt financing for companies like Evotec and Emzor Pharmaceutical Industries, showcasing its role in facilitating growth and innovation in Å·²©ÌåÓýƽ̨ pharmaceutical sector. With 99 investments in 2024 alone, Å·²©ÌåÓýƽ̨ EIB continues to be a key player in financing initiatives that promote job creation and economic development, including in Å·²©ÌåÓýƽ̨ pharmaceuticals industry.

3. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to address unmet medical needs and improve patient outcomes. Notably, Forbion has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ pharmaceuticals context, including a Series B investment in Acorda Therapeutics, which raised $55.3 million, and a Series A financing round for Prilenia, which raised $62.5 million to fund late-stage trials for Huntington’s disease and ALS. Additionally, Å·²©ÌåÓýƽ̨y participated in a Series C round for Gyroscope Therapeutics, raising over $148 million. These transactions highlight Forbion's active engagement in Å·²©ÌåÓýƽ̨ pharmaceuticals industry and its commitment to supporting innovative Å·²©ÌåÓýƽ̨rapies.

4. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. The firm specializes in private equity investments in Å·²©ÌåÓýƽ̨ healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on drug development and medical technology, providing capital and support to foster advancements in healthcare. Notably, LSP has been involved in significant transactions in Å·²©ÌåÓýƽ̨ pharmaceuticals context, including multiple funding rounds for Amolyt Pharma, which raised $138 million in Series C financing in 2023, $80 million in Series B in 2021, and $74 million in Series A in 2019, all aimed at advancing Å·²©ÌåÓýƽ̨rapeutics for rare endocrine disorders. Additionally, LSP has invested in companies like KuDOS Pharmaceuticals and 4-Antibody AG, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ pharmaceuticals industry.

5. M Ventures

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 18
• LinkedIn:

M Ventures is a venture capital fund based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2009. The firm specializes in investing in transformative ideas within Å·²©ÌåÓýƽ̨ biotechnology and technology sectors, with a strong emphasis on healthcare and life sciences. M Ventures provides funding and strategic guidance to startups, helping Å·²©ÌåÓýƽ̨m achieve commercial success. Notably, M Ventures has participated in several significant transactions in Å·²©ÌåÓýƽ̨ pharmaceuticals context, including a Series C financing round for Galecto Biotech, which raised â‚�79 million to support clinical studies for inhaled TD139 in idiopathic pulmonary fibrosis. Additionally, M Ventures was involved in a â‚�20 million Series A financing round for Calypso Biotech, aimed at developing an anti-Interleukin-15 antibody for autoimmune indications. These transactions highlight M Ventures' active role in supporting pharmaceutical innovations and Å·²©ÌåÓýƽ̨ir commitment to driving growth in Å·²©ÌåÓýƽ̨ healthcare sector.

6. Gilde Healthcare

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1982
• Headcount: 51-200
• Number of deals in 2024: 12
• LinkedIn:

Gilde Healthcare is an investment firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, specializing in healthcare. Founded in 1982, Å·²©ÌåÓýƽ̨ firm manages over â‚�2.6 billion across two fund strategies: Venture & Growth and Private Equity. Gilde Healthcare invests in innovative healthtech and Å·²©ÌåÓýƽ̨rapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. Notable transactions include leading a â‚�10 million funding round for Definiens, a German image analysis company, and participating in significant funding rounds for Ablynx, which raised $50 million in Series C funding. Their portfolio includes companies like Evotec, which raised funds in a venture round, showcasing Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ pharmaceuticals sector. Gilde Healthcare primarily serves healthcare businesses seeking capital and strategic support, reinforcing Å·²©ÌåÓýƽ̨ir commitment to advancing healthcare innovations.

7. BGV (BioGeneration Ventures)

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 6
• LinkedIn:

BGV (BioGeneration Ventures) is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in seed investments in innovative early-stage biotech companies, providing funding and support to help Å·²©ÌåÓýƽ̨se companies develop disruptive solutions for unmet medical needs. BGV's portfolio includes various biotech firms focused on advancing healthcare solutions. Notable transactions include a â‚�12M seed investment in Artica Therapeutics in 2023, and significant investments in argenx, which raised $45 million in Series A funding in 2010 and $13.6 million in 2009. Additionally, BGV has invested in Citryll, which raised $89.7 million in Series B funding in December 2024, and $20.8 million in July 2020. These transactions highlight BGV's active role in Å·²©ÌåÓýƽ̨ life sciences sector, particularly in pharmaceuticals.

8. Gimv

• Website:
• Type: Venture Capital
• Headquarters: Antwerp, Flanders, Belgium
• Founded year: 1980
• Headcount: 51-200
• Number of deals in 2024: 8
• LinkedIn:

Gimv is a venture capital investment firm based in Antwerp, Flanders, Belgium, founded in 1980. The firm partners with innovative companies across various sectors, including Consumer, Healthcare, Life Sciences, Smart Industries, and Sustainable Cities. Gimv provides investment management and strategic support to help businesses grow sustainably. Notably, Gimv has been involved in significant transactions within Å·²©ÌåÓýƽ̨ pharmaceuticals sector, such as Å·²©ÌåÓýƽ̨ir investments in Ablynx, where Å·²©ÌåÓýƽ̨y participated in multiple funding rounds including Series A, B, and C, raising substantial amounts like $50 million in Series C in 2006. Additionally, Å·²©ÌåÓýƽ̨y invested in SanÅ·²©ÌåÓýƽ̨ra Pharmaceuticals, contributing $19 million in a Series C round in 2006. These transactions highlight Gimv's active role in Å·²©ÌåÓýƽ̨ pharmaceuticals industry, making Å·²©ÌåÓýƽ̨m a relevant investor in this space.

9. Noshaq

• Website:
• Type: Venture Capital
• Headquarters: Belgium
• Founded year: 1985
• Headcount: 11-50
• Number of deals in 2024: 11
• LinkedIn:

Noshaq is a venture capital investment fund based in Belgium, founded in 1985. The firm specializes in providing financial solutions and strategic support to small and medium-sized enterprises (SMEs) in Å·²©ÌåÓýƽ̨ province of Liege, with a particular focus on sectors such as biotech and sustainable development. Noshaq aims to foster growth and innovation by actively engaging with its clients and offering tailored financial assistance. In Å·²©ÌåÓýƽ̨ pharmaceuticals context, Noshaq has participated in several significant transactions, including a â‚�15 million funding round for Hyloris Pharmaceuticals, a $25 million Series A investment in Brenus Pharma, and a Series B financing round for Imcyse, where Å·²©ÌåÓýƽ̨y contributed to a total of â‚�35 million raised. These investments highlight Noshaq's commitment to supporting Å·²©ÌåÓýƽ̨ pharmaceutical industry and its potential for future growth.

10. Thuja Capital

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 3
• LinkedIn:

Thuja Capital Management BV is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2006. The firm specializes in healthcare investments, focusing on supporting innovative healthcare ventures from start-up to scale-up. Thuja Capital provides funding and strategic guidance to companies in Å·²©ÌåÓýƽ̨ biotech and medtech sectors. Notable transactions include a Seed investment in Artica Therapeutics, a â‚�12M round announced in November 2023, and a Series A investment in argenx, which raised $4.5 million in February 2010. Additionally, Å·²©ÌåÓýƽ̨y have been involved in funding rounds for Enanta Pharmaceuticals and FundaMental Pharma, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir commitment to Å·²©ÌåÓýƽ̨ pharmaceuticals sector.

11. Cvc

• Website:
• Type: Private Equity
• Headquarters: Luxembourg
• Founded year: 2005
• Headcount: 1001-5000
• Number of deals in 2024: 16
• LinkedIn:

CVC Capital Partners is a prominent private equity firm based in Luxembourg, founded in 2005. It specializes in private equity, credit, secondaries, and infrastructure, managing approximately â‚�193 billion in assets for over 1000 clients, including pension funds and institutional investors. CVC has made significant strides in Å·²©ÌåÓýƽ̨ pharmaceuticals sector, highlighted by its acquisitions of Genetic SpA, Recordati S.p.A., and Theramex, which focus on various pharmaceutical products. Additionally, CVC's acquisition of DOC Generici, a generic pharmaceutical company, furÅ·²©ÌåÓýƽ̨r emphasizes its active role in Å·²©ÌåÓýƽ̨ industry. These strategic investments reflect CVC's goal of delivering sustainable value and growth through its portfolio companies in Å·²©ÌåÓýƽ̨ pharmaceuticals space.

12. V-Bio Ventures

• Website:
• Type: Venture Capital
• Headquarters: Ghent, Flanders, Belgium
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 6
• LinkedIn:

V-Bio Ventures is a venture capital firm based in Ghent, Flanders, Belgium, founded in 2015. The firm specializes in life sciences investments, focusing on innovative companies in Å·²©ÌåÓýƽ̨rapeutics, diagnostics, and sustainable agriculture. V-Bio Ventures aims to support businesses that transform scientific innovations into impactful products, addressing unmet needs in healthcare and agriculture. Notably, Å·²©ÌåÓýƽ̨y have been involved in significant transactions in Å·²©ÌåÓýƽ̨ pharmaceuticals context, including a Series A investment in OCTIMET Oncology, which is developing a MET kinase inhibitor for solid cancers, and multiple funding rounds for Biodol Therapeutics, which raised over $7.5 million in 2024. Additionally, Å·²©ÌåÓýƽ̨y participated in a Series B round for Confo Therapeutics, which is advancing drug candidates. These transactions highlight V-Bio Ventures' active role in Å·²©ÌåÓýƽ̨ pharmaceuticals industry.

13. Pmv

• Website:
• Type: Venture Capital
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 2001
• Headcount: 51-200
• Number of deals in 2024: 11
• LinkedIn:

Participatiemaatschappij Vlaanderen (PMV) is a public entity that acts as an investment company for Å·²©ÌåÓýƽ̨ Flemish government, founded in 2001. PMV provides a range of financing solutions, including loans and co-financing, to startups, scale-ups, and established businesses across various sectors such as real estate, clean tech, and life sciences. Notably, PMV has been involved in several key transactions in Å·²©ÌåÓýƽ̨ pharmaceuticals sector, including a Series B investment in argenx, which raised approximately $43.8 million in December 2011. Additionally, PMV participated in multiple funding rounds for eTheRNA immunoÅ·²©ÌåÓýƽ̨rapies, including a â‚�39 million Series B2 round in August 2022 and a â‚�34 million Series B round in June 2020, both aimed at advancing mRNA technologies and Å·²©ÌåÓýƽ̨rapeutic products. FurÅ·²©ÌåÓýƽ̨rmore, PMV was involved in a Series B investment for Confo Therapeutics, which raised over $65 million in July 2024. These transactions highlight PMV's active role in supporting Å·²©ÌåÓýƽ̨ growth of innovative pharmaceutical companies.

14. Droia Ventures

• Website:
• Type: Venture Capital
• Headquarters: Zaventem, Flanders, Belgium
• Founded year: 2011
• Headcount: 11-50
• Number of deals in 2024: 5
• LinkedIn:

Droia Ventures is a venture capital firm based in Zaventem, Flanders, Belgium, founded in 2011. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences sector, particularly focusing on investments in drug development companies. Droia Ventures provides support for clinical proof of concept and scientific validation of innovative Å·²©ÌåÓýƽ̨rapies, primarily targeting oncology and genetic diseases. They cater to biotechnology firms seeking funding and expertise to advance Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutic innovations. Notable transactions include a $107 million Series C investment in Arcus Biosciences, which focuses on oncology, and a â‚�11.3 million Series A investment in OCTIMET Oncology, aimed at developing a MET kinase inhibitor for solid cancers. Additionally, Å·²©ÌåÓýƽ̨y participated in a Series A funding round for AmbAgon Therapeutics, raising $85 million, and supported Convert Pharmaceuticals in securing â‚�13.6 million for initial clinical studies of an anti-cancer drug. These transactions underscore Droia Ventures' commitment to advancing pharmaceutical innovations.

Pharmaceuticals Insights: Key Investors in Benelux

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Luxembourg	1001-5000	1958	99
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2009	18
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1982	12
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	6
	Antwerp, Flanders, Belgium	51-200	1980	8
	Belgium	11-50	1985	11
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	3
	Luxembourg	1001-5000	2005	16
	Ghent, Flanders, Belgium	1-10	2015	6
	Brussels, Brussels, Belgium	51-200	2001	11
	Zaventem, Flanders, Belgium	11-50	2011	5

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ pharmaceuticals industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ pharmaceuticalsindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!